Financial Performance - The company's revenue for the year ended December 31, 2025, reached RMB 21,790.0 million, representing a year-on-year growth of 16.7%[2] - Gross profit increased by 30.9% to RMB 10,018.5 million, with a gross margin of 46.0%, up from 41.0%[2][5] - Net profit rose by 45.3% to RMB 5,733.2 million, while profit attributable to shareholders increased by 46.3% to RMB 4,908.3 million[2][5] - The group's IND pre-service revenue increased by 31.9% to approximately RMB 9,314.3 million, accounting for 42.8% of total revenue[47] - Early clinical development service revenue decreased by 30.8% to approximately RMB 2,639.0 million, representing 12.1% of total revenue[47] - Late clinical development service and commercialization revenue grew by 26.4% to approximately RMB 9,460.7 million, making up 43.4% of total revenue[47] - Revenue from the top five customers increased by 4.5% to approximately RMB 5,687.6 million, accounting for 26.1% of total revenue[48] - The total comprehensive income for the year was RMB 6,820.0 million, significantly higher than RMB 3,116.7 million in the previous year[108] - The company's profit attributable to owners for the year ended December 31, 2025, was RMB 4,908,343,000, an increase of 46.2% from RMB 3,356,081,000 in 2024[109] - Total comprehensive income attributable to owners for the same period was RMB 6,013,420,000, up 138.5% from RMB 2,524,660,000 in 2024[109] Operational Highlights - The company added 209 integrated projects in 2025, bringing the total to 945, reinforcing its position as a preferred partner for global biopharmaceutical innovation[3] - The total value of uncompleted orders increased to USD 23.7 billion, including USD 11.5 billion in service orders and USD 12.2 billion in potential milestone payments[5] - The company has established partnerships with the top 20 global pharmaceutical companies, enhancing its integrated capabilities from discovery to commercialization[6] - The CRDMO platform includes approximately 800 scientists providing comprehensive biopharmaceutical discovery solutions[8] - The company is advancing over 160 bispecific antibody projects, leveraging its proprietary WuXiBodyTM platform, which has achieved over 50 collaborations globally[10] - The company is developing next-generation T cell engagers (TCEs) and other innovative therapies to address tumor and autoimmune diseases[9][11] - The company has successfully implemented a "follow and win molecules" strategy, resulting in a stable increase in late-stage clinical and commercial production projects, with 74 and 25 projects respectively as of the reporting period[22] - The company has successfully built an integrated platform for advanced therapeutic modalities, significantly enriching its service portfolio and ensuring continuous growth driven by innovation[24] Research and Development - Research and development expenses increased by 11.4% to approximately RMB 853.4 million, reflecting ongoing investment in innovation and technology[58] - The company plans to invest approximately 10% of the proceeds (RMB 1,089.9 million) in mRNA-related technologies, with RMB 1,035.8 million already utilized[100] - The company has developed a single B cell technology that significantly enhances existing capabilities, supporting the discovery of valuable lead molecules for challenging targets[14] - The company launched the EffiXTM microbial expression platform, enabling high-yield, high-quality, and stable microbial-derived bioproducts, supporting various technology modes for development and production[27] Financial Health and Stability - The company reported a significant increase in free cash flow for the year, indicating strong financial health and operational efficiency[5] - The total cash and bank balances increased by 45.3% from approximately RMB 10,186.2 million on December 31, 2024, to approximately RMB 14,800.8 million on December 31, 2025, primarily due to net cash inflows from operating activities and proceeds from asset sales in Europe[79] - The total borrowings decreased by 60.4% from approximately RMB 2,636.2 million on December 31, 2024, to approximately RMB 1,042.9 million on December 31, 2025, mainly due to the repayment of most bank loans in the second half of 2025[82] - The capital-to-debt ratio decreased from 5.8% on December 31, 2024, to 2.0% on December 31, 2025, due to loan repayments and an increase in total equity from net profit and new share issuance[87] - The group has established a comprehensive financing and fiscal policy to effectively manage capital needs and optimize cash flow, ensuring financial stability and supporting sustainable growth[80] Market and Strategic Initiatives - The company plans to strengthen its integrated platform through strategic investments in cutting-edge technologies and optimize global capacity layout by 2026[43] - The company is considering strategic acquisitions to bolster its market position, with a budget of $200 million allocated for potential deals[158] - The company signed a strategic memorandum of understanding with the Qatar Free Zone Authority to establish a core hub in Qatar, expanding its regional layout[38] - The company is focused on expanding its CRDMO services, which are critical for its growth strategy in the biopharmaceutical sector[112] Compliance and Governance - The company is committed to compliance with regulatory standards and operational excellence while focusing on geopolitical developments and tariff policies[43] - The company is committed to maintaining high levels of corporate governance and has complied with all applicable codes during the reporting period[97] - The company has received multiple awards for its quality services and commitment to ESG practices, including the "Best CDMO" awards in various categories[40] Employee and Talent Management - Total employee costs for the year ended December 31, 2025, were approximately RMB 5,880.2 million, compared to RMB 5,073.3 million in 2024, an increase of 15.9%[93] - The company maintained a key talent retention rate of approximately 96.4%[93] - The company has adopted various equity incentive plans to reward eligible participants for their contributions[94] Future Outlook - The company provided an optimistic outlook for the next quarter, projecting revenue growth of 20% to 25%[158] - New product launches are expected to contribute an additional $100 million in revenue over the next year[158] - Market expansion efforts include entering three new countries, which are projected to add $30 million in revenue within the first year[158]

Financial Performance - Revenue increased by 13% to approximately RMB 363.5 million for the year ended December 31, 2025[3] - Operating profit rose by 28% to approximately RMB 123.8 million[3] - Profit attributable to shareholders increased by 9% to approximately RMB 116.6 million[3] - Basic earnings per share were RMB 0.059, up from RMB 0.054[5] - Total comprehensive income for the year was RMB 112.872 million, compared to RMB 107.236 million in the previous year[6] - Operating profit for 2025 was RMB 172,834,000, compared to RMB 159,696,000 in 2024, reflecting a growth of 8.5%[19] - The company's operating profit for the year was approximately RMB 123.8 million, representing a 28% increase from RMB 96.6 million in 2024[50] - Net profit attributable to shareholders was approximately RMB 116.6 million, a 9% increase from RMB 106.6 million in 2024, with basic earnings per share at RMB 0.059[53] Assets and Liabilities - Non-current assets decreased to RMB 379.1 million from RMB 392.9 million[7] - Current assets increased to RMB 607.8 million from RMB 538.3 million[7] - Net assets rose to RMB 838.8 million from RMB 762.2 million[7] - Trade receivables for 2025 amount to RMB 14,295,000, with a net amount of RMB 6,873,000 after deducting provisions for losses, compared to RMB 7,235,000 in 2024[25] - Trade payables for 2025 total RMB 33,698,000, down from RMB 36,891,000 in 2024[26] - The group's equity attributable to shareholders as of December 31, 2025, is approximately RMB 834.8 million, an increase from RMB 758.5 million in 2024[56] - The net debt ratio remains at net cash status, with the current ratio improving to 5.4 times, up from 3.4 times in 2024[56] Cash Flow and Dividends - Cash and bank balances amounted to approximately RMB 569.3 million[3] - Proposed final dividend of HKD 0.02 per share[3] - The proposed final dividend for the year ending December 31, 2025, is HKD 0.02 per share, totaling approximately RMB 35,579,000, compared to RMB 37,198,000 for 2024[24] - The company has proposed a final dividend of HKD 0.02 per share for the year ending December 31, 2025, subject to shareholder approval[78] Revenue Sources - The revenue from product sales was RMB 213,422,000, while royalty income was RMB 150,122,000, representing a growth of 9.3% and 18.2% respectively compared to the previous year[16] - Total other income for 2025 was RMB 53,689,000, an increase from RMB 51,060,000 in 2024[17] - The revenue from licensing fees increased by 18% to approximately RMB 150.1 million, driven by a higher number of licensed footwear products and accessories[46] - Wholesale product sales revenue reached approximately RMB 189.4 million, up 9% from RMB 174.5 million in 2024, primarily due to increased sales to franchisees[47] - Retail revenue from "Daphne Lab" and "Daphne" brands amounted to approximately RMB 24.0 million, a 15% increase from RMB 20.8 million in 2024, attributed to the addition of new stores[47] Market and Strategy - The company has identified only one reportable segment, focusing on the distribution and sale of footwear products and accessories primarily in mainland China[15] - The company plans to enhance its online strategy and invest in both mature platforms and emerging channels to maintain steady growth in a competitive digital retail environment[29] - The brand's online sales channels continued to grow, supported by a systematic expansion of both online and offline networks[31] - The company plans to continue a cautious and flexible strategy in channel layout, advancing both online and offline business development[67] - The company aims to optimize its franchise network based on macroeconomic conditions and retail trends, with a focus on enhancing brand strength and consolidating market leadership[67] Operational Efficiency - The company is enhancing supply chain management through digital processes and unified shipping systems, improving operational efficiency and product quality stability[43] - Operating expenses rose to approximately RMB 120.6 million, compared to RMB 117.1 million in 2024, mainly due to increased employee benefits and marketing expenses[49] - Employee benefit expenses, including director remuneration, are approximately RMB 49.4 million, an increase of 6% year-on-year from RMB 46.5 million in 2024, due to an increase in headcount and discretionary bonuses[63] Future Plans - The company plans to replicate the successful "Daphne Lab" model in high-potential "new first-tier cities" at an appropriate time[67] - The group will continue to invest in innovative marketing activities and immersive experiences to enhance brand influence and consumer engagement for the "Daphne Lab" brand[66] - The group aims to enhance its core competitiveness by optimizing the entire value chain, including product quality, design innovation, and supply chain optimization[64] Compliance and Governance - The company has adopted the Corporate Governance Code and has complied with all applicable provisions for the year ending December 31, 2025[72] - The audit committee has reviewed the consolidated financial statements for the year ending December 31, 2025, and found no discrepancies in the accounting treatments adopted by the company[74]

Financial Performance - The company achieved total revenue of RMB 5.468 billion for the year ended December 31, 2025, representing a year-on-year growth of 13.7%[12] - Adjusted net profit reached RMB 414 million, a significant increase of 161.3% year-on-year, reflecting improved operational efficiency and AI-enabled capabilities[12] - The gross profit reached RMB 1,772.3 million, an increase of 16.3% compared to the previous year, indicating improved revenue quality[24] - The total expenses as a percentage of revenue decreased to 30.6%, down 4.6 percentage points year-on-year, indicating improved operational efficiency[24] - The adjusted net profit for 2025 was RMB 414.0 million, compared to RMB 158.5 million in 2024, reflecting significant operational improvement[66] - Cash and cash equivalents at the end of 2025 totaled RMB 1,720.1 million, down from RMB 2,044.7 million at the end of 2024[67] - Net cash generated from operating activities was RMB 450.9 million, significantly up from RMB 99.3 million in 2024[68] - The company reported a net cash outflow from financing activities of RMB 3,944.6 million, compared to RMB 38.4 million in 2024[68] - The company has a debt-to-asset ratio of 25.13% as of December 31, 2025[113] Business Growth and User Engagement - The enterprise health management business generated revenue of RMB 1.306 billion, marking a robust growth of 40.6% year-on-year, driven by the expansion of service scale[12] - The company reported a 1.5 times increase in the average new policy amount for health insurance clients, indicating enhanced customer engagement and value[12] - The M3 policy conversion rate for clients using the company's health services exceeded 15%, showcasing effective service activation and customer retention strategies[13] - The number of paying users increased to nearly 35 million, reflecting a year-on-year growth of 11.4%[26] - The company has served over 6,700 paid corporate clients, reflecting an 83.1% growth compared to 2024, highlighting its core competitiveness in corporate health management[15] - The enterprise health management business revenue grew by 40.6% year-on-year, accounting for 23.9% of total revenue, an increase of 4.6 percentage points[24] AI and Technological Innovation - AI contributes approximately 4.5% to gross profit, enhancing service efficiency and creating new health demand, driving revenue growth[18] - The company has launched a medical AI product system to enhance service delivery and operational efficiency[26] - The AI medical system achieved a diagnostic accuracy rate of 95.1% across over 11,300 diseases, with a multi-disciplinary consultation accuracy rate nearing 90% for complex diseases[54] - AI services covered 100% of the company's individual clients, with nearly 12 million annual users of AI doctors, contributing approximately 4.5% to gross profit[54] Service Expansion and Network Development - The offline service network has expanded to over 5,100 partner hospitals, more than 240,000 pharmacies, and over 4,400 health checkup suppliers, creating a comprehensive medical service system[14] - The company has integrated its "Four Arrivals" service system (to line, to hospital, to home, to enterprise) to provide a one-stop medical and elderly care service[22] - The company aims to deepen collaboration with the Ping An Group to build a distinctive managed medical model in China[20] - The company has covered 100 cities nationwide with its home elderly care services, emphasizing its commitment to providing quality care for the elderly[15] - The home care service has covered 100 cities nationwide, with a monthly active rate of 84% and a 100% response rate for the "smart guardian" alarm system[44] Employee and Management Practices - The company employs a total of 1,668 employees, primarily located in various cities in China, including Shanghai, Guangzhou, Shenzhen, Hefei, Beijing, and Qingdao[77] - The company has established a compensation system based on "cash salary + benefits + long-term incentives," with competitive remuneration to retain employees[77] - The company has a stable relationship with its employees, supported by various training policies and internal and external training opportunities[77] - The board of directors includes experienced executives with backgrounds in finance, internet, and healthcare sectors, enhancing the company's strategic direction[79][80][81][83][84] Corporate Governance and Compliance - The company has established appropriate insurance arrangements for directors' responsibilities[146] - There are no significant transactions or contracts involving directors or related entities during the fiscal year ending December 31, 2025[144] - The company has not entered into any management contracts for the operation of its business during the reporting period[147] - The board believes that the contractual arrangements and related transactions are crucial for the group's legal structure and business, and they are conducted on normal commercial terms, deemed fair and reasonable for the group and its shareholders[194] Strategic Initiatives and Future Plans - The company aims to solidify its leading position in the industry and provide a solid foundation for business expansion through the proceeds from the placement[99] - The company plans to allocate HKD 544.9 million for potential investments and acquisitions in domestic companies and overseas expansion by December 31, 2025[100] - The company will continue to focus on user-oriented service development, optimizing AI applications in various medical service scenarios[57] - The company aims to enhance its service capabilities by integrating a comprehensive service network and upgrading supply chain management to create a win-win ecosystem[57]

Revenue and Profitability - Revenue for the six months ended December 31, 2025, was HKD 41,389,000, a decrease of 35.4% compared to HKD 64,022,000 for the same period in 2024[4] - Gross profit for the same period was HKD 10,363,000, down 36.5% from HKD 16,300,000 year-on-year[4] - The total revenue from contracts with customers was HKD 41,389,000, a decline of 35% compared to HKD 64,022,000 in the prior year[16] - Revenue from the manufacturing and sale of health and household products decreased to HKD 41,196,000, down 34% from HKD 62,575,000 in the previous year[15] - The coal mining segment's revenue decreased by approximately 86.7% to about HKD 193,000, with a loss of approximately HKD 681,000 compared to a profit of HKD 903,000 in the previous period[62] Losses and Financial Performance - The company reported a net loss of HKD 14,074,000 for the period, a reduction of 84.8% compared to HKD 92,615,000 in the same period last year[5] - The total loss for the period was HKD 9,259,000, with a segment loss of HKD 8,578,000 from health and household products and HKD 681,000 from mining operations[14] - The company reported a comprehensive loss before tax from continuing operations of HKD (14,074,000), significantly improved from a loss of HKD (36,880,000) in the previous year[15] - The company reported a consolidated loss attributable to owners of approximately HKD 14,074,000 for the period, compared to a loss of HKD 36,945,000 in the previous period[57] Assets and Liabilities - Non-current assets totaled HKD 614,641,000 as of December 31, 2025, down from HKD 656,462,000 at the end of June 2025[6] - Current assets increased to HKD 149,385,000 from HKD 88,506,000, reflecting improved liquidity[6] - Total liabilities decreased to HKD 355,130,000 from HKD 485,874,000, indicating a stronger balance sheet[7] - The company's equity increased to HKD 464,955,000 from HKD 259,094,000, showing significant growth in shareholder value[7] - The company's total liabilities as of December 31, 2025, were HKD 110,127,000, with HKD 110,119,000 attributed to health and household products[14] Cash Flow and Financing - The company reported a net cash inflow from financing activities of HKD 88,202,000, primarily due to proceeds from a rights issue of HKD 111,965,000[9] - The cash and cash equivalents increased by HKD 79,155,000, bringing the total to HKD 99,927,000 as of December 31, 2025[9] - The company’s operating cash outflow for the period was HKD 9,737,000, an improvement from HKD 11,948,000 in the previous year[9] - The company raised approximately HKD 112,000,000 through a rights issue to improve its financial position in a challenging business environment[57] Shareholder Information - The total issued and paid-up share capital as of December 31, 2025, was 1,718,697,510 shares[45] - Major shareholders include Low Thiam Herr with 40.66% (698,753,840 shares) and Lim Kim Chai with 25.61% (440,206,570 shares) of the total 1,718,697,510 shares issued as of December 31, 2025[90] - The company did not recommend any interim dividend for the six months ended December 31, 2025, consistent with the previous year[22] Business Operations and Strategy - The company has ceased its property development and first-tier land development business in China following the sale of its wholly-owned subsidiary[10] - The company is in the process of acquiring Elise Beauty Group Limited for a total consideration of HKD 62,500,000, which includes the issuance of 341,903,719 shares at HKD 0.1828 per share[54] - The company has ceased issuing new loans as of the reporting period, with outstanding loans previously issued having terms of 6 to 12 months[32] - The group plans to reduce its workforce to approximately 50 employees by June 2026 as part of its cost optimization strategy[67] Market Conditions and Future Outlook - The group expects continued pressure on sales and gross margins in the health and household products segment due to ongoing challenges in the market environment, including US-China trade tensions[67] - The acquisition of Elise Beauty is expected to be completed in the first half of 2026, which will allow the group to establish a foothold in the Chinese beauty and skincare sector[68] - The coal production plan for 2026 has been revised from 600,000 tons to 21,000 tons due to regulatory requirements from Minerba[69] Compliance and Governance - The company has established an audit committee consisting of four independent non-executive directors to oversee financial reporting and internal controls[92] - The company has adopted new and revised Hong Kong Financial Reporting Standards effective from July 1, 2025, with no significant impact on its accounting policies[12]

Company Information - King's Flair International (Holdings) Limited is registered in the Cayman Islands with stock code 6822[2] Financial Announcements - The company clarified its announcement regarding the annual results for the year ending December 31, 2025[3] - The announcement maintains all other information unchanged[4] Shareholder Information - Shareholders must submit their share transfer documents by May 20, 2026, to vote at the annual general meeting[3]

Financial Performance - Total revenue for 2025 reached RMB 457.29 billion, a year-on-year increase of 25.0%[5] - Adjusted net profit for 2025 was RMB 39.17 billion, reflecting a year-on-year growth of 43.8%[5] - The company achieved an annual profit of RMB 41.6 billion in 2025, compared to RMB 23.6 billion in 2024, reflecting strong financial performance[37] - The net profit for the year ending December 31, 2025, increased by 76.3% to RMB 41.6 billion from RMB 23.6 billion in 2024[68] - Basic earnings per share rose to RMB 1.62 in 2025, compared to RMB 0.95 in 2024, reflecting improved profitability[175] Revenue Breakdown - The mobile and AIoT segment accounted for 76.8% of total revenue in 2025, while the smart electric vehicle and AI innovation segment contributed 23.2%[38] - In 2025, Xiaomi's "Mobile × AIoT" segment revenue reached RMB 351.2 billion, a historical high, with a year-on-year growth of 5.4%[18] - Xiaomi's smartphone business revenue in 2025 was RMB 186.4 billion, with a gross margin of 10.9%, and global smartphone shipments reached 165.2 million units[19] - By the end of 2025, Xiaomi's IoT and lifestyle consumer products revenue hit a historical high of RMB 123.2 billion, growing 18.3% year-on-year, with a gross margin of 23.1%[23] - The internet services business generated revenue of RMB 37.4 billion in 2025, a year-on-year increase of 9.7%, with a gross margin of 76.5%[27] Segment Performance - The smartphone and AIoT segment generated revenue of RMB 35.12 billion in 2025, up 5.4% year-on-year[6] - The smart electric vehicle and AI innovation segment saw revenue soar to RMB 10.61 billion, a staggering 223.8% increase year-on-year[6] - Revenue from smart electric vehicles and AI innovation business surged by 223.8% from RMB 32.8 billion for the year ending December 31, 2024, to RMB 106.1 billion for the year ending December 31, 2025[45] - The number of smart electric vehicle deliveries increased by 200.4% from 136,854 units for the year ending December 31, 2024, to 411,082 units for the year ending December 31, 2025[45] User Engagement - Monthly active users reached a record high of 754.1 million by December 2025, a 7.4% increase year-on-year[7] - The number of connected IoT devices reached 1.08 billion, representing a 19.3% year-on-year growth[7] - Xiaomi's AIoT platform connected 1,079.2 million IoT devices by December 31, 2025, a year-on-year increase of 19.3%[23] Research and Development - Research and development expenditure for 2025 was RMB 33.1 billion, a 37.8% increase compared to the previous year[10] - Xiaomi's cumulative R&D spending over the past five years reached RMB 105.5 billion, with plans to exceed RMB 200 billion in the next five years[10] - R&D expenses increased by 37.8% from RMB 24.1 billion in 2024 to RMB 33.1 billion in 2025, reflecting higher investment in electric vehicles and AI[58] Operating Expenses - Operating expenses rose by 32.6% from RMB 55 billion in 2024 to RMB 73 billion in 2025, with significant increases in R&D and sales expenses[57] - Sales and marketing expenses surged by 19.5% from RMB 8.3 billion in Q3 2025 to RMB 9.9 billion in Q4 2025, primarily due to increased advertising related to mobile × AIoT and smart electric vehicles[137] Cash Flow and Investments - The total capital expenditure for 2025 was RMB 18,157.0 million, with significant investments in smart electric vehicles and AI-related innovations totaling RMB 12,023.8 million[165] - The company reported a decrease in cash and cash equivalents of RMB 8,595.9 million for Q4 2025[160] - As of December 31, 2025, cash and cash equivalents amounted to RMB 26,914.4 million, down from RMB 35,548.0 million at the beginning of the period[160] Inventory and Liabilities - Inventory for the mobile AIoT segment rose to RMB 74.76 billion in 2025, up from RMB 60.91 billion in 2024, an increase of 22.8%[191] - Total liabilities increased to RMB 241.77 billion in 2025 from RMB 213.95 billion in 2024, marking a rise of 13%[179] Market Strategy - Xiaomi's new retail strategy resulted in approximately 18,000 Mi Home stores in mainland China by December 2025, with a net increase of over 3,000 stores[17] - The company aims to deliver 550,000 vehicles in 2026, focusing on expanding its sales network with 477 car sales stores established in 138 cities by the end of 2025[33]

KECK SENG INVESTMENTS (HONG KONG) LIMITED 激成投資（香港）有限公司 （於香港註冊成立之有限公司） 網址：www.keckseng.com.hk （股份代號：184） 二零二五年度全年業績公佈 激成投資（香港）有限公司（「本公司」）董事會（「董事會」）謹此公佈本公司及其附屬公 司（「本集團」）與及聯營公司截至二零二五年十二月三十一日止年度之綜合全年業績。此等 業績已由董事會轄下之審核及合規委員會審閱，集團核數師畢馬威會計師事務所已就初步業績 公布所載，集團截至二零二五年十二月三十一日止年度之綜合財務狀況報表、綜合損益表、綜 合損益及其他全面收益表以及相關附註，與集團該年度經審計綜合財務報表所載數字核對一 致。畢馬威會計師事務所就此執行的工作，並不構成鑒證業務，因此畢馬威會計師事務所並無 對初步業績公布發表任何意見或鑒證結論。 截至二零二五年十二月三十一日止年度之本公司權益股東應佔綜合溢利為257,477,000 港元 （每股基本盈利0.757 港元），而二零二四年度為255,841,000港元（每股基本盈利0.752港 元）。 董事會建議派發本年度末期股息每股 0.09 ...

Financial Performance - Revenue for the year ended December 31, 2025, is projected to be RMB 1,248,103,000, representing a 7.3% increase from RMB 1,162,786,000 in 2024[5] - Gross profit for the same period is expected to reach RMB 911,314,000, a 12.0% increase compared to RMB 813,522,000 in 2024[5] - The adjusted profit before tax is forecasted to be RMB 96,279,000, a significant turnaround from a loss of RMB 35,834,000 in 2024, marking a 368.7% improvement[5] - Net profit is anticipated to be RMB 93,165,000, recovering from a loss of RMB 48,856,000 in the previous year, reflecting a 290.7% increase[5] - The company's total revenue for the year ending December 31, 2025, was approximately RMB 1,248.1 million, representing a year-on-year growth of about 7.3%[19] - The net profit for the year was approximately RMB 93.2 million, marking a turnaround from loss to profit, with a year-on-year increase of about 290.7%[19] - The adjusted net profit for the year was approximately RMB 96.7 million, also indicating a turnaround from loss to profit, with a year-on-year growth of about 325.8%[19] - The group achieved a turnaround from loss to profit primarily due to an increase in overall revenue scale and a higher proportion of high-margin channel income, leading to growth in gross margin[20] Product Development and Market Strategy - The company aims to strengthen its position in the female-oriented gaming market and expand its product matrix with various new titles targeting different user demographics[9] - New products include titles like "Ling Yun Nuo" and "Fu Sheng Wei Qing Ge," which focus on immersive storytelling and aesthetics appealing to female players[9] - The company plans to implement localized strategies and creative marketing to enhance its competitive edge in the cultural creative industry[10] - The group launched the "Floating Life" series IP, with flagship products "Floating Life: Memories of Linglong" and "Floating Life: For You, My Song," contributing stable cash flow[28] - The group has successfully expanded its user base and explored emerging market growth points through a collaborative R&D strategy that enhances product success rates[21] - The company aims to enhance its market presence through new product development and strategic partnerships, focusing on innovation and technology advancements[58] Technology and Innovation - The company is actively investing in AI technology and has led investments in multiple AI companies to enhance its business innovation and sustainable development[12] - The company is focusing on building a comprehensive AI application system that covers the entire process of development, publishing, and operation, emphasizing the integration of AI in gaming[11] - The "AI + gaming" strategy focuses on technological innovation to upgrade the gaming industry and enhance player experience, with a comprehensive AI application system covering development, publishing, and operations[24] - The company is exploring innovative applications of AI in emotional companionship and interactive experiences, particularly in the field of entertainment technology[12] Corporate Governance and Social Responsibility - The company is committed to corporate social responsibility, enhancing user information security, and has been certified under the international ISO/IEC 27001 information security management standard[13] - The company is committed to corporate social responsibility, engaging in various charitable activities and promoting sustainable development initiatives[41] - The company has implemented measures to protect minors, including real-name verification and time restrictions on gaming for underage users[43] - The company has established a regulated capital and investment management policy to monitor and control potential risks associated with investment activities[110] Financial Position and Assets - Non-current assets decreased to RMB 202,718,000 in 2025 from RMB 220,499,000 in 2024, reflecting a decline of approximately 8.05%[48] - Current assets increased to RMB 915,563,000 in 2025, up from RMB 878,251,000 in 2024, representing a growth of about 4.8%[48] - Total liabilities decreased to RMB 191,006,000 in 2025 from RMB 247,431,000 in 2024, a reduction of approximately 22.8%[50] - The company's total equity rose to RMB 1,239,998,000 in 2025, compared to RMB 1,150,076,000 in 2024, marking an increase of about 7.8%[50] - The company’s cash and cash equivalents decreased to RMB 153,015,000 in 2025 from RMB 334,825,000 in 2024, a decline of approximately 54.4%[48] Shareholder and Dividend Information - The board has proposed a final dividend of HKD 0.02 per ordinary share for the year ending December 31, 2025[6] - The board proposed a final dividend of HKD 0.02 per share, with total cash dividends exceeding RMB 790 million since the company's listing[39] - The company has been actively repurchasing shares, with approximately 4.1% of total issued shares bought back under the share incentive plan[39] Employee and Management - The group has a total of 912 employees as of December 31, 2025, an increase from 887 employees as of December 31, 2024[102] - The group has established a share incentive plan, with a total of 85,070,600 restricted share units granted to directors, senior management, and employees[74] - The company has implemented appropriate consultation processes for significant decisions involving the board and senior management[133] Audit and Compliance - The audit committee has reviewed the consolidated financial statements for the year ending December 31, 2025, confirming compliance with applicable accounting principles and sufficient disclosures[138] - The group's auditor, PwC, has confirmed that the financial figures in the preliminary announcement are consistent with the audited consolidated financial statements[139] Future Outlook - The overall performance indicates a positive outlook for the upcoming fiscal year, with expectations of continued revenue growth driven by strategic initiatives and market expansion efforts[54][56]

Financial Performance - The Company reported total revenue of HK$12,936,000 for the six months ended December 31, 2025, a decrease of 8.7% from HK$14,168,000 in the same period of 2024[7]. - Hotel income decreased to HK$9,005,000, down 5.7% from HK$9,550,000 year-on-year[7]. - Gross profit for the period was HK$4,870,000, representing a decline of 23.6% compared to HK$6,386,000 in the previous year[7]. - The Company recorded a net loss before taxation of HK$382,000, contrasting with a profit of HK$5,741,000 in the prior period[7]. - Total comprehensive income attributable to owners of the Company was a loss of HK$16,728,000, compared to a gain of HK$8,860,000 in the same period last year[8]. - Basic and diluted earnings per share were both HK0 cents, down from HK1.17 cents in the previous year[8]. - For the six months ended December 31, 2025, the company reported a profit of HK$10,000, compared to HK$6,127,000 for the same period in 2024, reflecting a significant decrease in profitability[12]. Assets and Liabilities - Non-current assets decreased to HK$242,499,000 from HK$266,342,000 as of June 30, 2025[9]. - Current assets remained relatively stable at HK$289,316,000, slightly down from HK$289,391,000[9]. - Total current liabilities decreased to HK$25,504,000 from HK$29,158,000, indicating improved short-term financial health[9]. - The Company has maintained a strong cash position with bank balances and cash amounting to HK$5,212,000[9]. - As of December 31, 2025, total equity decreased to HK$473,300,000 from HK$490,028,000 as of June 30, 2025, representing a decline of approximately 3.5%[10]. - The net assets of the company as of December 31, 2025, were HK$473,300,000, down from HK$490,028,000, indicating a reduction of about 3.4%[10]. - The total non-current liabilities decreased to HK$33,011,000 as of December 31, 2025, from HK$36,547,000 as of June 30, 2025, a reduction of about 9.2%[10]. - The company’s lease liabilities decreased to HK$213,000 as of December 31, 2025, from HK$390,000 as of June 30, 2025, indicating a decrease of approximately 45.4%[10]. Cash Flow and Investments - Net cash used in operating activities for the six months ended December 31, 2025, was HK$8,788,000, compared to HK$7,215,000 for the same period in 2024, indicating an increase in cash outflow[13]. - The company generated net cash of HK$4,691,000 from investing activities for the six months ended December 31, 2025, down from HK$5,980,000 in the previous year[13]. - Cash and cash equivalents at the end of the period decreased to HK$106,876,000 from HK$111,115,000, marking a decline of approximately 3.9%[13]. - The accumulated losses as of December 31, 2025, were HK$1,667,087,000, slightly improved from HK$1,700,711,000 as of July 1, 2025[12]. Segment Performance - The Group operates four reportable segments: hotel hospitality, money lending services, liquor and wine, and investments in listed securities[26]. - For the six months ended December 31, 2025, total segment revenue was HK$12,936,000, a decrease from HK$14,168,000 for the same period in 2024, representing a decline of approximately 8.7%[28]. - The hotel hospitality business generated revenue of HK$9,005,000, while the money lending services and liquor segments reported revenues of HK$0 and HK$8,000 respectively[28]. - Segment profit for investments in listed securities was HK$6,836,000, contributing positively to the overall segment profit of HK$2,807,000 despite losses in other segments[28]. - The hotel hospitality segment recorded a loss of approximately HK$3.6 million for the six months ended December 31, 2025, compared to a loss of approximately HK$3.0 million for the same period in 2024[111]. Loans and Credit Management - The Group's loan portfolio consisted of four individual borrowers and three corporate borrowers, with a total outstanding principal amount and interest receivables of approximately HK$248.15 million as of December 31, 2025[129]. - The Group has not solicited new clients or granted new loans recently, focusing instead on examining the existing loan portfolio and recovering outstanding loans[128]. - A credit policy has been adopted to manage the money lending business, including compliance with laws, credit assessments, and collateral requirements[142]. - Credit risk assessments are performed before granting loans by reviewing financial information and assessing the financial condition of potential borrowers[143]. Market and Economic Outlook - The global economic outlook is impacted by inflationary pressures and geopolitical uncertainty, which the Group will continue to monitor[162]. - The depreciation of the Japanese Yen is expected to attract more tourists to Japan, which may benefit the Group's business[162]. - The Group aims to control costs while seizing investment opportunities to strengthen its core business and maintain stable returns to shareholders[164]. Legal Proceedings - Legal proceedings have been initiated against borrower A, with an amended writ filed in July 2025, but service has been unsuccessful[132]. - Borrower B has an outstanding principal amount of HK$10,491,007 at an interest rate of 16%, with legal proceedings initiated in November 2019, but no enforcement actions have been taken due to jurisdictional issues[133]. - The Group is currently engaged in legal actions to recover debts from borrower C, with the bankruptcy process ongoing[135]. Employee and Operational Changes - The Group's employee count increased to 52 as of December 31, 2025, up from 28 as of June 30, 2025[193][196]. - The management has shifted focus from acquiring new customers to assessing the existing loan portfolio and recovering outstanding loans due to changes in management[130].

Financial Performance - WH Group Limited reported a revenue increase of 8.0% to $28,026 million for the year ending December 31, 2025, compared to $25,941 million in 2024[3]. - Operating profit rose by 8.7% to $2,612 million in 2025, up from $2,404 million in 2024[3]. - The profit attributable to owners of the company increased by 8.2% to $1,591 million, with basic earnings per share rising to 12.40 cents from 11.47 cents in the previous year[3]. - The company's revenue increased by 8.0% to $28.026 billion in 2025, driven by higher pork sales and average prices of meat products[14]. - Operating profit rose by 8.7% to $2.612 billion, primarily due to significant profit growth in the pork business[14]. - Revenue growth rate for 2025 is 8.0%, an increase of 9.1 percentage points from -1.1% in 2024[23]. - Net profit margin improved to 6.8% in 2025, up by 0.2 percentage points from 6.6% in 2024[23]. - The gross profit for 2025 was $4,987 million, compared to $5,200 million in 2024, indicating a decrease of about 4.1%[63]. - The net profit for the year was $1,891 million, up from $1,853 million in 2024, reflecting an increase of approximately 2.1%[64]. Market Segmentation - Pork sales volume increased by 8.6% to 4,089 thousand tons, while meat product sales volume decreased by 1.5% to 3,054 thousand tons[2]. - The Chinese market accounted for 30.3% of the group's revenue and 35.8% of operating profit in 2025, compared to 32.5% and 39.2% in 2024, respectively[5]. - In North America, the business contributed 54.3% of revenue and 53.3% of operating profit, showing slight increases from 53.0% and 49.4% in 2024[5]. - Pork revenue increased by 10.1% to $11.383 billion, with North America showing a notable growth of 19.2%[19]. - The meat products segment accounted for 82.0% of the company's operating profit and 50.6% of total revenue in 2025, down from 92.9% and 52.6% respectively in 2024[14]. Production and Operations - The total pork production in China increased by 4.1% to 5,940 thousand tons, with a total of 720 million live pigs produced, up 2.4%[6]. - The total number of pigs slaughtered increased by 7.9% to 48.942 million heads in 2025[20]. - The company's poultry business saw a 12.6% increase in the number of chickens, geese, and turkeys slaughtered, totaling approximately 392 million[21]. - The utilization rates for meat products production capacity were 65.3% in China, 83.2% in North America, and 84.2% in Europe[22]. - The operating profit for the pork segment surged by 62.4% to $578 million, largely due to improved conditions in the U.S. pork farming sector[20]. Financial Position - Cash and bank balances reached $2.388 billion as of December 31, 2025, compared to $2.055 billion in 2024[28]. - Net cash generated from operating activities remained stable at $2.526 billion in 2025, slightly up from $2.519 billion in 2024[29]. - Total outstanding loans amounted to $3.649 billion as of December 31, 2025, an increase from $3.330 billion in 2024[32]. - The company maintained a current ratio of 1.9 as of December 31, 2025, consistent with 2024[28]. - The total asset return rate decreased to 9.1% in 2025, down by 0.4 percentage points from 9.5% in 2024[23]. - The company's financial costs decreased by 0.7% to $146 million in 2025, with an average interest rate on outstanding loans of 2.55%[36]. Investments and Acquisitions - The company plans to invest up to $1.3 billion in a new state-of-the-art processing facility in Sioux Falls, South Dakota, expected to commence construction in the first half of 2027 and begin operations by the end of 2028[37]. - The company completed the acquisition of Nathan's Famous for $102 per share, enhancing its meat product brand portfolio and expected to drive growth in high-margin products[39]. - The acquisition of Wolf Group, a leading German producer of premium sausages and convenience foods, was completed, expected to accelerate growth in the European market[40]. - The company sold its goose slaughtering business in Poland for a net amount of $21 million, realizing a pre-tax gain of $11 million, allowing a focus on core business areas[42]. Employee and Compensation - Total employee count as of December 31, 2025, is approximately 106,000, with 49,000 in China, 35,000 in North America, and 22,000 in Europe[50]. - Total compensation expenses for 2025 amounted to $4.348 billion, an increase of 4.8% from 2024, primarily due to global wage inflation and stock compensation related to the Smithfield incentive plan[50]. Sustainability and Governance - The company is committed to sustainable protein options and has updated its greenhouse gas reduction targets, with a focus on water resource risk assessment[58]. - The company received an AA- rating from the Hang Seng Sustainable Development Index and improved its MSCI ESG rating to A, reflecting recognition of its sustainability efforts[59]. - The company has maintained compliance with the corporate governance code as per the listing rules for the year ending December 31, 2025[98]. Dividends and Shareholder Information - A special cash dividend of HKD 0.18 per share was declared, totaling approximately HKD 25.24 billion (around $3.24 billion)[25]. - The company plans to distribute a final dividend of HK$0.41 per share for the year ending December 31, 2025, pending shareholder approval[82]. - The total interim and final dividends for the year will amount to HKD 0.61 per share, compared to HKD 0.50 per share for the previous year[101].